Video

Dr. Powles on pivotal enfortumab vedotin data in bladder cancer

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Thomas Powles, MBBS, MRCP, MD, director, Barts Cancer Institute, discusses findings from the pivotal EV-301 trial of enfortumab vedotin (Padcev). Based on findings from the EV-301 trial and the EV-201 trial, the FDA recently granted the antibody-drug conjugate a standard approval for the treatment of patients with locally advanced or metastatic urothelial cancer who have previously received a PD-1/PD-L1 inhibitor and platinum-containing chemotherapy; or patients who are ineligible for cisplatin-containing chemotherapy and have previously received 1 or more prior lines of therapy.

      Related Content
      © 2025 MJH Life Sciences

      All rights reserved.